Bcl-2 is an anti-apoptotic and anti-proliferative protein over-expressed in several dierent human cancers including breast. Gain of Bcl-2 function in mammary epithelial cells was superimposed on the WAP-TAg transgenic mouse model of breast cancer progression to determine its eect on epithelial cell survival and proliferation at three key stages in oncogenesis: the initial proliferative process, hyperplasia, and cancer. During the initial proliferative process, Bcl-2 strongly inhibited both apoptosis and mitotic activity. However as tumorigenesis progressed to hyperplasia and adenocarcinoma, the inhibitory eects on mitotic activity were lost. In contrast, anti-apoptotic activity persisted in both hyperplasias and adenocarcinomas. These results demonstrate that the inhibitory eect of Bcl-2 on epithelial cell proliferation and apoptosis can separate during cancer progression. In this model, retention of anti-apoptotic activity with loss of anti-proliferative action resulted in earlier tumor presentation.
Introduction
Bcl-2 was originally described as a candidate oncogene in human lymphomas (Tsujimoto et al., 1984) , and later identi®ed as an anti-apoptotic factor (Korsmeyer, 1992) . Subsequently it was found to modulate entry into the cell cycle and repress cell proliferation in addition to its anti-apoptotic action (Adams and Cory, 1998; Gil-Gomez et al., 1998; O'Reilly et al., 1997a,b; Borner, 1996; Linette et al., 1996; Pietenpol et al., 1994) . In cell lines, the anti-proliferative eect of Bcl-2 can be genetically separated from its anti-apoptotic eect (Uhlmann et al., 1996; Huang et al., 1997) . Deletion of a non-conserved region has been associated with loss of anti-proliferative action while antiapoptotic functions are maintained. Similar separable actions on apoptosis and proliferation have been described for the Epstein-Barr virus homolog of bcl-2, BHRF1 (Theodorakis et al., 1996) . Bcl-2 is commonly expressed in a number of human cancers including human breast and cervix (Saegusa et al., 1995; Pillai et al., 1996; . A transgenic mouse model of cancer progression was utilized to investigate the antiapoptotic and anti-proliferative activity of Bcl-2 at three distinct stages during cancer progression: during the initial proliferative process, hyperplasias and cancers. In these experiments, gain of Bcl-2 function in mammary epithelial cells was introduced into the whey acidic protein (WAP)-Simian virus 40 T antigen (TAg) mouse model of breast cancer progression. In WAP-TAg transgenic mice, tumorigenesis is initiated by expression of TAg and evolves from an initial proliferative process through hyperplasia to cancer (Tzeng et al., 1993; Li et al., 1996b) .
The anti-apoptotic and anti-proliferative eects of Bcl-2 segregated during tumor progression. During the initial proliferative process gain of Bcl-2 function was both anti-mitotic and anti-apoptotic. However as the cancer progressed to hyperplasias and tumors, the antimitotic eect became undetectable whereas the antiapoptotic activity persisted. This resulted in shortened tumor latency.
Results

Gain of Bcl-2 function in TAg expressing mammary epithelial cells reduced the rate of apoptosis throughout cancer progression
Both WAP-TAg and WAP-TAg/WAP-bcl-2 mice exhibited homogeneous expression of TAg in their lobulo-alveolar mammary epithelial cells during the initial proliferative process at day 18 of pregnancy ( Figure 1a,d ). The presence of TAg triggered an increase in both mitosis and apoptosis (Figure 1c ,f) (Li et al., 1996b) . TAg expression in the mammary epithelial cells increased the apoptotic rate from the 0.2% measured in mammary epithelial cells from nontransgenic mice at day 18 of pregnancy to 5.9% in the WAP-TAg mice (Figure 2) (Li et al., 1996b) .
The presence of Bcl-2 in the WAP-TAg/WAP-bcl-2 mice (Figure 1k ) reduced the apoptotic rate to 2.1% during the initial proliferative process (Figures  1f and 2 ). As the tissue transitioned to hyperplasia and cancer, Bcl-2 continued to inhibit apoptosis. In WAP-TAg mice the rate of apoptosis declined as the cells became hyperplastic and then cancerous. It fell from 5.9% during the initial proliferative process to 2.8% in the hyperplasias and 1.7% in the Grade 4 ± 5 adenocarcinomas (Figures 2 and 3c ). In the WAPTAg/WAP-bcl-2 mice, the addition of Bcl-2 reduced the apoptotic rate from 2.1% during the initial proliferative process to 1.9% in the hyperplasias and 1.0% in the Grade 4 ± 5 adenocarcinomas (Figures 2  and 3f ). Expression of Bcl-2 in the adenocarcinomas was con®rmed by Western blot analysis (Figure 3g ). No alterations in expression levels of the apoptosis inducing proteins Bax and Bad or the Bcl-2 interacting protein Bag-1 (Schorr et al., 1999a,b; Kitada et al., 1998; Zapata et al., 1998) were detected in the presence or absence of Bcl-2.
Gain of Bcl-2 function reduced mitotic activity during the initial proliferative process but not in hyperplasias or adenocarcinomas Expression of TAg in mammary epithelial cells increased mitotic activity. In clinical specimens the incidence of mitosis is reported directly as the number of mitotic ®gures per high power (406) ®eld. Nontransgenic control mice and WAP-bcl-2 single transgenic mice demonstrated only one mitotic ®gure in ten high power ®elds (ten HPF) at day 18 pregnancy (Table 1 ). In contrast, WAP-TAg mice exhibited 20 mitotic ®gures/ten HPF at the same timepoint.
The presence of Bcl-2 in the WAP-TAG/WAP-bcl-2 mice reduced the number of mitotic ®gures to 1.2 mitotic ®gures/ten HPF during the initial proliferative process. In contrast, the presence of Bcl-2 did not reduce the number of mitotic ®gures per ten high power ®elds in either hyperplastic tissue or the adenocarcinomas (Table 1) .
In order to compare the rate of mitosis throughout cancer progression, the percentage of mitotic ®gures was calculated. Presentation of mitotic activity as a percentage of the total number of cells controls for the dierent number of cells per high power ®eld during the initial proliferative process as compared to the hyperplasias and adenocarcinomas. The mitotic rate remained at slightly over 2% in the WAP-TAg mice as the cells progressed through the initial proliferative process to hyperplasia and adenocarcinoma (Figure 4 ).
In contrast, mitotic activity in the WAP-TAg/WAPbcl-2 mice increased dramatically from 0.12% during the initial proliferative process to just over 2% in the hyperplasias and adenocarcinomas. This demonstrates that the inhibitory eect of Bcl-2 on mitotic activity measured during the initial proliferative process became unapparent as the cells progressed to hyperplasia.
Cell cycle analyses were performed to determine if the alterations in mitotic activity during the initial proliferative process in the WAP-TAg/WAP-bcl-2 mice correlated with changes in cell cycle progression. Gain of Bcl-2 function in the WAP-TAg/WAP-bcl-2 mice during the initial proliferative process reduced the percentage of cells in G2-M and S phase as compared to WAP-TAg mice (Table 2 ). In contrast, no reduction in G2-M or S phase was found in the adenocarcinomas from the WAP-TAg/WAP-Bcl-2 mice ( Figure 5 ). This supports the concept that Bcl-2's inhibitory eect on cell proliferation was limited to the initial proliferative process and was lost as the cells progressed to cancer.
Gain of Bcl-2 function in the WAP-TAg mouse model of cancer progression shortened the time to appearance of ®rst palpable tumor but did not alter the histology of the adenocarcinomas Gain of Bcl-2 function shortened the time to the appearance of the ®rst palpable tumor (Figure 6a ). The early reduction in proliferative activity did not delay progression to cancer. Instead the reduction in apoptotic activity dominated the presentation resulting in reduced tumor latency.
The histological features of the adenocarcinomas in the presence and absence of Bcl-2 were compared. Adenocarcinomas from the WAP-TAg mice were classi®ed into ®ve histological grades ranging from well to poorly dierentiated (see Materials and methods). Grade 1 adenocarcinomas are more well dierentiated and Grade 5 adenocarcinomas are poorly dierentiated. There was no signi®cant variation in the distribution of the dierent grades in the presence of Bcl-2 ( Figure 6b ).
Discussion
Our results demonstrate that Bcl-2 can have both antiapoptotic and anti-mitotic activities on mammary epithelial cells in vivo in an early precancerous lesion. However, in the WAP-TAg mouse model of cancer progression only the anti-apoptotic activity persisted throughout carcinogenesis. There was no apparent anti-mitotic eect in the hyperplasias and adenocarcinomas.
Previous studies in tissue culture cells have emphasized that the anti-apoptotic and anti-proliferative actions of Bcl-2 are genetically separable, mechanistically distinct, and may vary between dierent cell types (Huang et al., 1997; Uhlmann et al., 1996; Pietenpol et al., 1994) . Our results indicated that the anti-apoptotic activity was selectively retained during cancer progression in the WAP-TAg model. Signi®cantly, when mammary cancers were induced by the chemical carcinogen DMBA, the anti-proliferative activity of Bcl-2 was maintained in the mammary gland Figure 2 Changes in apoptotic index during cancer progression in WAP-TAg and WAP-TAg/WAP-bcl-2 mice. The apoptotic index in WAP-TAg mice during the initial proliferative process and in the Grade 4 ± 5 adenocarcinomas was signi®cantly dierent from that of the WAP-TAg/WAP-bcl-2 mice (P=0.001 for each). Each value represents the mean+s.e.m. from a group of mice. The apoptotic index was calculated after quantitation of apoptotic mammary epithelial cells detected in situ. At least 1000 cells were counted for each mouse. n=5 for WAP-TAg mice at all three stages and WAP-TAg/WAP-bcl-2 mice during the initial proliferative process. N=3 for WAP-TAg/WAP-bcl-2 mice hyperplasias and adenocarcinomas and WAP-bcl-2 mice. Only tumors graded as 4 ± 5 adenocarcinomas were used for the quantitation of apoptosis to control for dierences related to tumor grade cancers while the anti-apoptotic action was reduced (Murphy KL, Kittrell FS, Gay JP, JaÈ ger R, Medina D and Rosen JM. Bcl-2 expression inhibits mammary tumor development in dimethylbenz(a)anthracenetreated transgenic mice, submitted.) Selective retention of one or the other activities had dierent impacts on the course of cancer progression in the two models. In the WAP-TAg model, persistent anti-apoptotic activity coupled with loss of the anti-mitotic action resulted in earlier cancer presentation. In the DMBA model, retention of anti-proliferative activity and absence of apoptotic eects led to a delay in tumor presentation. Taken together, these results suggest that Bcl-2's ability to block proliferation or apoptosis or both may be cell speci®c. This could be due to molecular interactions inherent to the dierent malignant processes induced by either TAg or DMBA.
Signi®cant dierences between these two malignant processes include the potential to mobilize p53, activity and availability of the retinoblastoma family of proteins including pRb, p107 and p130, and responsiveness to signaling from transforming growth factorb (TGF-b). In the WAP-TAg model p53 is inactivated by binding to TAg (Li et al., 1996a) . In contrast, DMBA induced mammary tumors rarely exhibit p53 mutation and retain the ability to express active p53 (Jerry et al., 1994) . Expression of TAg in mammary epithelial cells in the WAP-TAg model impairs the activity of pRb, p107 and p130 (Zalvide et al., 1998) . Cells which express TAg are resistant to the action of TGF-b, at least in part due to the inactivation of pRb by binding to TAg (Franch et al., 1995; Basola et al., 1994; Moses, 1992) . Although information on the activity of pRb, p107 and p130 in DMBA induced mammary tumors is not available, growth of DMBA induced mammary tumors is enhanced by expression of a dominant-negative mutant type II TGF-b receptor (Bottinger et al., 1997) and inhibited by overexpression of TGF-b1 (Pierce et al., 1995) . In the WAP-TAg mouse model, the loss of active p53 in mammary epithelial cells is paralleled by the absence of p21 expression in agreement with results from other cell types (Li and Furth, unpublished results) . Figure 4 Changes in the percentage of mitotic cells during cancer progression in WAP-TAg and WAP-TAg/WAP-bcl-2 mice. The percentage of mitotic cells in the WAP-TAg mice was signi®cantly dierent from the percentage of mitotic cells in the WAP-TAg/ WAP-bcl-2 mice during the initial proliferative process (P50.006). The percentage of mitotic cells in the hyperplasias and adenocarcinomas of WAP-TAg mice were not signi®cantly dierent from the percentage in the hyperplasias and adenocarcinomas of the WAP-TAg/WAP-bcl-2 mice. Each value represents the mean+s.e.m. from a group of mice. The percentage of mitotic cells was calculated after quantitation of mitotic cells. At least 1000 cells were counted for each mouse. n=7 for the WAP-TAg mice during the initial proliferative process and in the hyperplasias, n=4 for the WAP-TAg/WAP-bcl-2 mice during the initial proliferative process and in the hyperplasias, n=6 for the WAP-TAg adenocarcinomas and n=3 for the WAP-TAg/ WAP-Bcl-2 adenocarcinomas. Only tumors graded as 4 ± 5 adenocarcinomas were used for the quantiation of mitosis to control for dierences related to tumor grade Compromised expression of p27 is expected from the loss of TGF-b signaling in the presence of TAg. Both p21 and p27 are negative regulators of the cell cycle. One mechanism which may contribute to the persistent Bcl-2 mediated inhibition of cell proliferation in the DMBA induced mammary cancers could be retention of the p21 and p27 signaling pathways in concert with persistent activity of at least some pRb family members, in contrast to the loss of these pathways and active proteins in the TAg induced mammary cancers.
Both Bcl-2 and p21 are reported to promote formation of E2F-p130 complexes, a feature of nonproliferating cells (Lind et al., 1999; Shiyanov et al., 1996) . Release of E2F promotes progression through the cell cycle. p21 has been shown to suppress cell growth by enhancing formation of E2F-p130 complexes through disruption of the interaction between the cyclin-dependent kinase Cdk2 and the E2F-p130 complex (Shiyanov et al., 1996) . p107 and p130 appear to both bind to Cdk2 and inhibit its activity (Coats et al., 1999; Castano et al., 1998; De Luca et al., 1997) . The activity of Cdk2 is also regulatable by Bcl-2 (Gil-Gomez et al., 1998) and over-expression of Bcl-2 in tissue culture cells has been shown to reduce the amounts of Cdk2 in the nucleus (Meikrantz et al., 1994) . These pathways can, at least to some extent, be regulated by titrating the quantities and activity of the dierent proteins. Cdk2 is activated during apoptosis (Hakem et al., 1999) and overexpression of Cdk2 can increase the rate of apoptosis even in the presence of Bcl-2 (Meikrantz and Schlegel, 1996) . At least in mitogen-starved fibroblasts, p130 can substitute for p21 and p27 when they are absent (Coats et al., 1999) . Over-expression of E2F-1 can over-ride growth suppression from TGF-b (Schwarz et al., 1995) and promote slowed but continuous cell cycling when over-expressed with Bcl-2 (Strom et al., 1998) .
It is possible that the observed changes in the ability of Bcl-2 to inhibit mitotic activity in the WAP-TAg model through cancer progression and the preservation of the inhibitory activity on cell proliferation in the DMBA model are due to titration of these dierent regulatory factors. In support of this hypothesis, protein expression levels of both Cdk2 and E2F-1 rise during the course of tumorigenesis in the WAPTAg model (Li and Furth, unpublished observations) . Over-expression of these cell cycle activating proteins in the cancers might over-ride the anti-proliferative eects of Bcl-2. Proof for this possibility or identification of an alternative mechanism will be found in future investigations.
Finally it will be important to determine if there are types of human cancers which exhibit selective retention of either the anti-apoptotic or anti-proliferative functions of Bcl-2 and ask if this correlates with the activity or expression level of other regulatory proteins. The pathophysiological role of Bcl-2 in human breast cancer is not completely understood. For example, the presence of Bcl-2 has been correlated with lower apoptotic rates in some but not all types of human breast cancers (Frankfurt et al., 1997; Sierra et al., 1996) . In primary breast cancers, Bcl-2 expression is frequently correlated with the presence of the estrogen receptor and this has been associated with a good response to combination treatment with hormones and chemotherapy (Gasparini et al., 1995; Ravaiolo et al., 1998) . Down-regulation of Bcl-2 expression due to inhibition of the estrogen receptor by hormonal treatments is one explanation for this positive correlation. In contrast, the presence of Bcl-2 in advanced breast cancers has been associated with resistance to chemotherapy (Bonetti et al., 1998) .
In conclusion, the anti-mitotic and anti-apoptotic activities of Bcl-2 in epithelial cells are separable in animal models of cancer progression. This will need to be directly examined in human cancers. Identi®cation of the mechanisms responsible for this segregation of activity could improve our utilization and understanding of Bcl-2 as a prognostic marker in dierent human cancers and provide new therapeutic targets for intervention in both precancerous and malignant lesions.
Materials and methods
Transgenic mice, mammary gland biopsies, and tumor progression studies Transgenic mice carrying either a whey acidic protein-simian virus 40 T antigen (WAP-TAg) hybrid gene (Tzeng et al., 1993; Li et al., 1996b) or a WAP-human bcl-2 hybrid gene (WAP-bcl-2) (JaÈ ger et al., 1997) were bred together. Nontransgenic, single, and double transgenic NMRI/C57b1/6 female mice were identi®ed using the polymerase chain reaction (JaÈ ger et al., 1997; Li et al., 1996b) . One hundred per cent of these WAP-TAg mice that undergo serial pregnancies develop mammary adenocarcinomas by the age of 9 months. Tumor development is multi-focal. Initial high level expression of TAg occurs at day 11 ± 13 of the ®rst pregnancy. Mammary gland tissue samples from eight single WAP-TAg and eight double WAP-TAg/WAP-bcl-2 transgenic mice were studied at three stages of breast cancer progression: during the initial proliferative process (day 18, ®rst pregnancy), hyperplasia, and cancer. Time of ®rst palpable tumor was determined by weekly physical exams. Fifty-eight WAP-TAg and 16 WAP-TAg/WAP-bcl-2 mice were followed to determine the time to ®rst palpable tumor. Five single transgenic WAP-bcl-2 and eight wild-type mice were studied as controls. Mammary gland biopsies of either the left or right fourth and ®fth mammary glands were performed on day 18 of the ®rst pregnancy to obtain tissue during the initial proliferative process (Li et al., 1996a) . When the ®rst palpable tumor was found, WAP-TAg and WAPTAg/WAP-bcl-2 mice were killed by cervical dislocation. Hyperplastic mammary tissue and adenocarcinoma tissue were obtained at autopsy. The experimental protocol was approved by the Institutional Animal Care and Use Committee.
Histological examination, immunohistochemistry, tumor grading, in situ detection of apoptotic cells, and quantitation of apoptosis Mammary gland specimens were ®xed in 10% neutral formalin and embedded in paran. Five-mm tissue sections were used for either hematoxylin and eosin (H&E) staining, TAg immunohistochemistry or in situ detection of apoptotic cells using the Apotag kit (Oncor, Gaithersburg, MD, USA) (Li et al., 1996a,b) . The initial proliferative process was histologically characterized by a single layer of epithelial cells containing cytologically bland nuclei organized into an alveolar structure. The hyperplasia was characterized by single to multilayered epithelial cells with nuclear atypia organized around a lumen and surrounded by increased connective tissue. These structures do not regress during postpregnancy involution of the gland. The adenocarcinomas which developed in the WAP-TAg and WAP-TAg/WAP-bcl-2 mice were categorized into ®ve grades as de®ned by the veterinary pathologist (RG Russell): Grade I: the acinar architecture with transformation of the epithelium, acinar epithelium is several cells in thickness, may be partially or completely ®lling the acinus. Grade II: well de®ned nodules and nests of neoplastic acinar epithelial cells with connective tissue stroma, loss of acini, peripheral layers of clumps and nests of cells with de®ned basal lamina. Grade III: variable acinar formation and sheets of neoplastic epithelial cells, localized areas exhibiting loss of basal lamina, epithelial cells extrude or stream locally as ribbons into connective tissue, may be accompanied by increased ®broplasia. Grade IV: acinar epithelium showing absence of acini or only poorly developed acinar formation, may exhibit sheets of pleomorphic epithelium which lack acinar formation or exhibit poorly developed acinar formation, increased numbers of mitotic ®gures, marked ®broplasia, may be localized areas of squamous dierentiation. Grade V: anaplastic. The percentage of cells undergoing apoptosis were calculated after counting over 1000 cells from each specimen. Mitotic ®gures were identi®ed on H&E stained sections and quantitated per ten high power (406) ®elds and as a percentage of mitotic cells after counting over 1000 cells from each specimen. Only tumors graded as 4 ± 5 adenocarcinomas were used for the quantitation of apoptosis and mitotic ®gures to control for dierences in these parameters related to tumor grade.
Cell cycle analysis and quantitation of mitotic ®gures
DNA¯ow cytometry was used to analyse the cell cycle using a modi®cation of Hedley's method (Demeril et al., 1996; Vindelov et al., 1983; Shankey et al., 1993) . Nuclear suspensions were prepared from three 50 mm tissue sections. A 4 mm section is cut before and after the 50 mm sections to con®rm that adequate material was submitted for DNA¯ow analysis. The samples were deparanized using two 50 min Xylene washes at 258C. The cells are then rehydrated using successive incubations with ethanol, 100, 95, 70 and 50% and distilled water. Between each concentration of ethanol, there was a 50 min incubation at 258C. To make a single cell suspension, the cells were treated with a 0.5% pepsin solution (Sigma Chemical Co., St. Louis, MO, USA) at 378C for 30 min. The ®nal nuclear suspension is stained with propidium iodide using the Vindelov technique (Vindelov et al., 1983) . The sample used for DNA¯ow cytometry was analysed on a FACScan¯ow cytometer (Becton Dickinson, San Jose, CA, USA). Histograms were generated to determine the percentage of cells in each phase of the cell cycle. As per recommendations of Shankey et al. (1993) for DNA¯ow analysis of paran embedded tissue, the ®rst peak was designated as the diploid G0/G1. Cell cycle analysis was performed using the Mod®t LT software (Verity Software, Topsham, ME, USA). Flow cytometry was used to analyse the cell cycle (Demeril et al., 1996; Vindelov et al., 1983; Shankey et al., 1993) . Cells were recovered from paran blocks cut into 50 mm tissue sections. Approximately 20 000 events were collected per sample for DNA¯ow analysis. Two 4-mm tissue sections were cut before and after the 50-mm sections to check histology.
Western blot analysis
Total protein was extracted from mammary tissue using RIPA buer (PBS, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS) with protease inhibitors phenylmethylsulfonyl¯ouride, aprotinin, and sodium orthovanadate. Twenty mg of protein from each sample was fractionated on a SDS ± 14% polyacrylamide gel, transferred (Li et al., 1996b) , and exposed to a 1 : 400 dilution of rabbit anti-Bcl-2 polyclonal antibody (sc#492) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), 1 : 400 dilution of rabbit anti-Bax polyclonal antibody (sc#493), 1 : 200 dilution of rabbit antiBad polyclonal antibody (sc#942) or 1 : 200 dilution of rabbit anti-Bag-1 antibody (sc#939) followed by exposure to a 1 : 5000 dilution of peroxidase conjugate antirabbit IgG polyclonal antibody (sc#2004) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Proteins were visualized using the ECL Western blotting protocol (Amersham, Arlington Heights, IL, USA).
Statistics
Standard error of the mean (s.e.m.) was calculated using Stat View 4.5 (Abacus Concepts, Inc., Berkeley, CA, USA).
Abbreviations WAP, whey acidic protein; TAg, Simian virus 40 large T antigen; WAP-TAg, a transgenic mouse model of breast cancer progression in which TAg expression is targeted to mammary epithelial cells using the WAP promoter; DMBA, dimethylbenz(a)anthracene; H&E, hematoxylin and eosin; HPF, high power ®elds; s.e.m. standard error of the mean
